Photo by atikahakhtar from unsplash
543 could be involved in patients with concomitant AA and AD. Based on the cases reported to date, there appears to be a potential risk of developing AA with dupilumab… Click to show full abstract
543 could be involved in patients with concomitant AA and AD. Based on the cases reported to date, there appears to be a potential risk of developing AA with dupilumab rather than a remission of pre-existing AA. We report the shortest time to onset of AA after dupilumab introduction. This is an unusual case of AA after a single injection of dupilumab. Clinicians should be aware of the risk of AA in patients treated with dupilumab. Scalp biopsies should be performed to better understand the pathophysiology of AA.
Keywords:
inhibitor induced;
dermatology;
class effect;
tnf inhibitor;
induced urticaria;
urticaria class
Journal Title: European Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!